Dr. Pingsheng Hu
Pingsheng Hu obtained his PhD in Karolinska Institute in Sweden. He has served in Pharmaceutical industry for many years such as AstraZeneca, Pharmcia, Biovitrum and other biotech companies. He is now Chairman and CEO of Sinorda in China. The company mainly focuses on cancer immunotherapy and drug development in unmet diseases.
Abstract
T-cell Immunotherapy for Solid Tumours
Dr. Pingsheng Hu, Guizhou Medical University Hospital
Although the application of immune checkpoint inhibitors is mainstream in clinical oncology, adoptive cell therapy (ACT) is rapidly growing for treatment of solid tumours in future.
There are several origins of T cell immunotherapies in developing currently that results very encouraging clinical output. We have developed tumour reactive T cells derived from Sentinel node (SN), in which lymphocytes receive the earliest tumour antigen stimulation, generating a strong specific immune memory for tumour recognition. The colorectal cancer (CRC) patients were treated in the pilot studies using the SLN-T cell-based adjuvant immunotherapy in Sweden and China. Our data showed that the SLN-T cell therapy is safe and feasible for postoperative CRC patients while improving the long-term survival of metastatic CRC.
Besides that, in our past year autologous CD8+ T cell therapy was used in our practices combined with other treatments for advanced-stage of castration-resistant prostate cancer, liver cancer and various of lymphomas, etc., that greatly improved the life quality and OS in the tailed clinical protocols.
Hong Kong International Oncology Symposium – Biomarkers and New Therapeutics
Hong Kong International Oncology Symposium – Biomarkers and New Therapeutics｜Webinar
Webinar｜Date: 27th March 2021 (Saturday)｜Time: 5:30 pm – 9:45 pm
